Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 7:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 1,912 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bleeding Disorder Clear all
Completed Phase 3 Interventional Results available

Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A

NCT02137850
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A
Interventions
turoctocog alfa pegol
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
0 Years to 6 Years · Male only
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
34
States / cities
Phoenix, Arizona • Long Beach, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 21, 2026, 7:36 AM EDT
Not yet recruiting No phase listed Observational

Continuous Assessment of Brain Blood Perfusion in Subarachnoid Hemorrhage Patients Using Near-Infrared Spectroscopy (NIRS)

NCT06932640
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Aneurysmal
Interventions
- Non-Invasive Near-infrared Spectroscopy (NIRS) device (HEM1 with Foresight Elite Sensor)
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 89 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 21, 2026, 7:36 AM EDT
Recruiting Not applicable Interventional

Auricular VNS Following Intracerebral Hemorrhage

NCT06799390
View directory record Official record
Conditions
Intracerebral Hemorrhage
Interventions
Auricular Vagus Nerve Stimulation, Sham Auricular Vagus nerve Stimulation
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 21, 2026, 7:36 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Rapid Point-of-Care Salivary Diagnostic for Periodontal Health

NCT02403297
View directory record Official record
Conditions
Gingivitis, Periodontal Disease
Interventions
Quik Check PD
Device
Lead sponsor
Innovative Diagnostics Inc
Industry
Eligibility
18 Years to 95 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 17, 2016 · Synced Oct 21, 2026, 7:36 AM EDT
Completed Phase 2Phase 3 Interventional

Tranexamic Acid for The Management of Bleeding Gastrointestinal Angioectasias

NCT07125508
View directory record Official record
Conditions
Anemia, Small Bowel Bleeding, Angioectasias
Interventions
Tranexamic Acid (TXA) treatment, Placebo
Drug
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Oct 21, 2026, 7:36 AM EDT
Completed Phase 3 Interventional Results available

HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients

NCT03569891
View directory record Official record
Conditions
Hemophilia B
Interventions
AAV5-hFIXco-Padua, Factor IX (FIX)
Genetic · Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older · Male only
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
19
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 21, 2026, 7:36 AM EDT
Completed Phase 4 Interventional Results available

EVOLVE Short DAPT Study

NCT02605447
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
3 months of dual antiplatelet therapy (DAPT), SYNERGY Stent System
Drug · Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
2,009 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
89
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Bakersfield, California + 75 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2020 · Synced Oct 21, 2026, 7:36 AM EDT
Withdrawn Phase 4 Interventional

Study Evaluating Inhibitor Specificity in Hemophilia A

NCT00151385
View directory record Official record
Conditions
Hemophilia A
Interventions
single blood draw
Procedure
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
7
States / cities
Atlanta, Georgia • Detroit, Michigan • New Hyde Park, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2012 · Synced Oct 21, 2026, 7:36 AM EDT
Completed Phase 3 Interventional Results available

LR769 in Congenital Hemophilia Patients With Inhibitors Undergoing Elective Surgery or Invasive Procedures

NCT02548143
View directory record Official record
Conditions
Hemophilia
Interventions
Coagulation Factor VIIa (Recombinant)
Biological
Lead sponsor
Laboratoire français de Fractionnement et de Biotechnologies
Industry
Eligibility
6 Months to 75 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2022 · Synced Oct 21, 2026, 7:36 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2

NCT04081220
View directory record Official record
Conditions
Thrombocythemia, Essential
Interventions
IMG-7289
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Oct 21, 2026, 7:36 AM EDT
Completed Phase 2 Interventional Results available

Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP

NCT00220727
View directory record Official record
Conditions
Purpura, Thrombocytopenic, Idiopathic
Interventions
Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified
Drug
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
12 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2016 · Synced Oct 21, 2026, 7:36 AM EDT
Terminated Phase 2 Interventional

Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia B

NCT03307980
View directory record Official record
Conditions
Hemophilia B
Interventions
PF-06838435 (formerly SPK-9001)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
17
States / cities
Sacramento, California • Metairie, Louisiana • New Orleans, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 21, 2026, 7:36 AM EDT
Completed Phase 2 Interventional Results available

Efficacy Study of a Facemask Device to Treat Hypotension

NCT00256724
View directory record Official record
Conditions
Hypotension
Interventions
Impedance Threshold Device, sham ITD
Device
Lead sponsor
Advanced Circulatory Systems
Industry
Eligibility
18 Years to 85 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 31, 2013 · Synced Oct 21, 2026, 7:36 AM EDT
Completed Phase 4 Interventional Results available

Early Whole Blood in Patients Requiring Transfusion After Major Trauma

NCT01227005
View directory record Official record
Conditions
Trauma/Injury Problem
Interventions
Transfusion of blood products
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 100 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2018 · Synced Oct 21, 2026, 7:36 AM EDT
Terminated Not applicable Interventional Results available

Impact of Fever Prevention in Brain Injured Patients

NCT02996266
View directory record Official record
Conditions
Fever, Ischemic Stroke, Intracerebral Hemorrhage, Subarachnoid Hemorrhage
Interventions
Targeted Temperature Management, Standard Care
Device · Other
Lead sponsor
C. R. Bard
Industry
Eligibility
21 Years to 85 Years
Enrollment
686 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
28
States / cities
Los Angeles, California • Palo Alto, California • Aurora, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 21, 2026, 7:36 AM EDT
Recruiting Phase 2 Interventional

Study of BB-031 in Acute Ischemic Stroke Patients (RAISE)

NCT06226805
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
BB-031, Placebo
Drug
Lead sponsor
Basking Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
15
States / cities
Scottsdale, Arizona • Burlingame, California • Long Beach, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 7:36 AM EDT
Completed Phase 1 Interventional

Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980

NCT00629837
View directory record Official record
Conditions
Hemophilia A
Interventions
Recomb. Factor VIII (Kogenate FS Liposome, BAY79-4980), Recombinant Factor VIII (Kogenate FS, BAY14-2222)
Biological
Lead sponsor
Bayer
Industry
Eligibility
12 Years to 60 Years · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
2
States / cities
Davis, California • Orange, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2014 · Synced Oct 21, 2026, 7:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Plastic Hat Trial to Prevent Hypothermia in Preterm Newborns in the Delivery Room

NCT00904228
View directory record Official record
Conditions
Hypothermia
Interventions
placement of plastic cap during delivery room stabilization, placement of routine cap during delivery room stabilization
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
Up to 1 Hour
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Oct 21, 2026, 7:36 AM EDT
Completed Not applicable Interventional

Prostate Biopsy, Transrectal vs. Transperineal: Efficacy and Complications

NCT04081636
View directory record Official record
Conditions
Prostate Cancer, PSA, Infection
Interventions
Systematic Transrectal biopsy (TR-Bx), Targeted Transrectal biopsy (TR-Bx), Systematic Transperineal biopsy (TP-Bx), Targeted Transperineal biopsy (TP-Bx)
Procedure
Lead sponsor
Albany Medical College
Other
Eligibility
Male only
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 21, 2026, 7:36 AM EDT
Completed No phase listed Observational

A Study Following People With Haemophilia A and B, With or Without Inhibitors, When on Usual Treatment (Explorer™6)

NCT03741881
View directory record Official record
Conditions
Haemophilia A, Haemophilia A With Inhibitors, Haemophilia B, Haemophilia B With Inhibitors
Interventions
No treatment given
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
12 Years and older · Male only
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
29
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Oct 21, 2026, 7:36 AM EDT
Not listed Phase 1Phase 2 Interventional

Safety and Feasibility of Hypertonic Saline Solution After Aneurysmal Subarachnoid Hemorrhage:

NCT02432157
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Cerebral Vasospasm, Hyponatremia
Interventions
HTS 3%, Standard fluid management
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 11, 2016 · Synced Oct 21, 2026, 7:36 AM EDT
Completed Phase 1 Interventional

Dose Finding and Safety Study of Deferoxamine in Patients With Brain Hemorrhage

NCT00598572
View directory record Official record
Conditions
Intracerebral Hemorrhage
Interventions
Deferoxamine Mesylate
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Oct 21, 2026, 7:36 AM EDT
Enrolling by invitation Not applicable Interventional

Rectal Evacuation Disorders and Straining-associated Symptoms in Bleeding Hemorrhoids

NCT07161765
View directory record Official record
Conditions
Bleeding Hemorrhoids, Rectal Evacuation Disorders
Interventions
Anorectal manometry
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 21, 2026, 7:36 AM EDT
Terminated Phase 3 Interventional Results available

The Hemophilia Inhibitor Eradication Trial

NCT04303572
View directory record Official record
Conditions
Hemophilia A With Inhibitor
Interventions
Eloctate ITI, Emicizumab
Drug
Lead sponsor
Margaret Ragni
Other
Eligibility
Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 21, 2026, 7:36 AM EDT